Irritable Bowel Syndrome (IBS) Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Irritable Bowel Syndrome Treatment Market size is expected to record an 8.6% CAGR between 2024 and 2032, spurred by heightened R and D efforts. Researchers are delving into new medications, dietary strategies, and therapeutic methods to effectively manage irritable bowel syndrome (IBS) symptoms and enhance the quality of life of patients.

Advances in gut microbiome research and the rise of personalized medicine are leading to the creation of treatments that cater specifically to individual patient needs. Furthermore, ongoing clinical trials are not only testing these innovative therapies but are also setting the stage for significant advancements in IBS management. For example, in April 2023, EnteroBiotix Limited initiated a clinical trial, dosing its first patient, to evaluate the efficacy of EBX-102-02, a full-spectrum microbiome therapeutic, in treating the syndrome.

The IBS treatment industry is segmented based on condition, drug class, dosage form, distribution channel, and region.

The market share from the IBS-C condition segment is expected to witness substantial growth through 2032, driven by increasing adoption for relieving symptoms and improving quality of life. New therapies are enhancing gut motility and addressing the unique challenges of IBS-C. Ongoing research is exploring medications to promote bowel movements and address associated discomfort, while dietary modifications and behavioral therapies are also integrated into treatment plans.

In terms of dosage form, the irritable bowel syndrome treatment market value from the powder segment is slated to generate notable revenue during 2024-2032. This is fueled by the rising need for offering a convenient and flexible option for patients. Powder form allows precise dosing and easy administration for enhancing patient compliance and treatment efficacy. Ongoing research is helping in developing powders that can deliver active ingredients effectively for targeting specific IBS symptoms and improving overall digestive health.

Europe irritable bowel syndrome treatment industry size is likely to record a notable CAGR through 2032 due to the rising acceptance of telemedicine. With remote consultations, patients enjoy enhanced convenience and broader access to specialist care. Telemedicine platforms empower healthcare providers to craft personalized treatment regimens and offer continuous monitoring, leading to improved IBS symptom management in the region.

Product Code: 10525

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of IBS
  - 3.2.1.2 Advancements in treatment options
  - 3.2.1.3 Growing awareness and diagnosis rates
  - 3.2.1.4 Favorable reimbursement policies
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Side effects of medications
  - 3.2.2.2 Alternative therapies and home remedies
3.3 Growth potential analysis
3.4 Brand analysis
- 3.4.1 Ironwood pharmaceuticals, Inc.
- 3.4.2 Bausch health
- 3.4.3 Astellas pharma, Inc.
- 3.4.4 Takeda pharmaceutical company limited
- 3.4.5 Sebela pharmaceuticals Inc.
- 3.4.6 Ardelyx
3.5 Regulatory landscape
3.6 Pipeline analysis
3.7 Reimbursement scenario
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Condition, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 IBS-D
5.3 IBS-C
5.4 IBS-M

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Antidiarrheals
6.3 Laxatives
6.4 Secretagogues/Prosecretory agents
6.5 Antispasmodics
6.6 Antibiotics
6.7 Retainagogues
6.8 Antidepressants/Neuromodulators
6.9 Other drug classes

Chapter 7 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Tablet
7.3 Liquid
7.4 Powder

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Brick and mortar
8.3 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Ardelyx
10.2 Astellas Pharma, Inc.
10.3 Bausch Health
10.4 Bayer
10.5 Ironwood Pharmaceuticals, Inc.
10.6 Johnson and Johnson
10.7 Sanofi
10.8 Sebela Pharmaceuticals Inc.
10.9 Takeda Pharmaceutical Company Limited
10.10 Validus Pharmaceuticals LLC